BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 2013;369:321-42. [PMID: 23463207 DOI: 10.1007/978-3-642-27340-7_13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Mitchell JK, McGivern DR. Mechanisms of hepatocarcinogenesis in chronic hepatitis C. Hepat Oncol 2014;1:293-307. [PMID: 30190964 DOI: 10.2217/hep.14.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Jee MH, Hong KY, Park JH, Lee JS, Kim HS, Lee SH, Jang SK. New Mechanism of Hepatic Fibrogenesis: Hepatitis C Virus Infection Induces Transforming Growth Factor β1 Production through Glucose-Regulated Protein 94. J Virol 2015;90:3044-55. [PMID: 26719248 DOI: 10.1128/JVI.02976-15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
3 Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape. J Immunol. 2014;193:783-796. [PMID: 24928988 DOI: 10.4049/jimmunol.1302563] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
4 Ahmed-Belkacem A, Guichou JF, Brillet R, Ahnou N, Hernandez E, Pallier C, Pawlotsky JM. Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral intervention. Nucleic Acids Res 2014;42:9399-409. [PMID: 25053847 DOI: 10.1093/nar/gku632] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
5 Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11:482-496. [PMID: 23748342 DOI: 10.1038/nrmicro3046] [Cited by in Crossref: 262] [Cited by in F6Publishing: 239] [Article Influence: 29.1] [Reference Citation Analysis]
6 Sugiyama R, Murayama A, Nitta S, Yamada N, Tasaka-Fujita M, Masaki T, Aly HH, Shiina M, Ryo A, Ishii K, Wakita T, Kato T. Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling. Oncotarget 2018;9:5627-40. [PMID: 29464023 DOI: 10.18632/oncotarget.23562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2014;281:4085-96. [PMID: 25039866 DOI: 10.1111/febs.12936] [Cited by in Crossref: 267] [Cited by in F6Publishing: 244] [Article Influence: 33.4] [Reference Citation Analysis]
8 Elkwafi G, Mohamed N, Elabbar F, Alnajjar R. Flavonoid content of the Libyan Onosma Cyrenaicum: isolation, identification, electronic chemical reactivity, drug likeness, docking, and MD study. J Biomol Struct Dyn 2021;:1-16. [PMID: 33685329 DOI: 10.1080/07391102.2021.1897046] [Reference Citation Analysis]
9 Liu D, Ndongwe TP, Puray-Chavez M, Casey MC, Izumi T, Pathak VK, Tedbury PR, Sarafianos SG. Effect of P-body component Mov10 on HCV virus production and infectivity. FASEB J 2020;34:9433-49. [PMID: 32496609 DOI: 10.1096/fj.201800641R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Hundt J, Li Z, Liu Q. Post-translational modifications of hepatitis C viral proteins and their biological significance. World J Gastroenterol 2013; 19(47): 8929-8939 [PMID: 24379618 DOI: 10.3748/wjg.v19.i47.8929] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
11 Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother 2014;58:2781-97. [PMID: 24590484 DOI: 10.1128/AAC.02386-13] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
12 Brown AS, Ackerley DF, Calcott MJ. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor. Molecules 2020;25:E4666. [PMID: 33066278 DOI: 10.3390/molecules25204666] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Murayama A, Momose H, Yamada N, Matsubayashi K, Muramatsu M, Hamaguchi I, Kato T. Performance Evaluation of In Vitro Screening and Diagnostic Kits for Hepatitis C Virus Infection. Front Cell Infect Microbiol 2022;11:793472. [DOI: 10.3389/fcimb.2021.793472] [Reference Citation Analysis]
14 Gawlik K, Gallay PA. HCV core protein and virus assembly: what we know without structures. Immunol Res 2014;60:1-10. [PMID: 24557493 DOI: 10.1007/s12026-014-8494-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, Hatzakis A, Prins M, Vickerman P, Lazarus JV. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9:e103345. [PMID: 25068274 DOI: 10.1371/journal.pone.0103345] [Cited by in Crossref: 151] [Cited by in F6Publishing: 142] [Article Influence: 18.9] [Reference Citation Analysis]
16 Zhang Y, Thai V, McCabe A, Jones M, MacNamara KC. Type I interferons promote severe disease in a mouse model of lethal ehrlichiosis. Infect Immun 2014;82:1698-709. [PMID: 24491580 DOI: 10.1128/IAI.01564-13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
17 Milewska A, Ner-Kluza J, Dabrowska A, Bodzon-Kulakowska A, Pyrc K, Suder P. MASS SPECTROMETRY IN VIROLOGICAL SCIENCES. Mass Spectrom Rev 2020;39:499-522. [PMID: 31876329 DOI: 10.1002/mas.21617] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol 2015;89:4387-404. [PMID: 25653444 DOI: 10.1128/JVI.02705-14] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
19 Arciello M, Gori M, Balsano C. Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress. Oxid Med Cell Longev. 2013;2013:971024. [PMID: 24371505 DOI: 10.1155/2013/971024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
20 Xiao F, Fofana I, Heydmann L, Barth H, Soulier E, Habersetzer F, Doffoël M, Bukh J, Patel AH, Zeisel MB, Baumert TF. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog 2014;10:e1004128. [PMID: 24830295 DOI: 10.1371/journal.ppat.1004128] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 8.8] [Reference Citation Analysis]
21 Perez-Berna AJ, Benseny-Cases N, Rodríguez MJ, Valcarcel R, Carrascosa JL, Gastaminza P, Pereiro E. Monitoring reversion of hepatitis C virus-induced cellular alterations by direct-acting antivirals using cryo soft X-ray tomography and infrared microscopy. Acta Crystallogr D Struct Biol 2021;77:1365-77. [PMID: 34726165 DOI: 10.1107/S2059798321009955] [Reference Citation Analysis]
22 Al-Hamoudi WK. Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol 2016;22:173-82. [PMID: 27184634 DOI: 10.4103/1319-3767.182453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Yokokawa H, Higashino A, Suzuki S, Moriyama M, Nakamura N, Suzuki T, Suzuki R, Ishii K, Kobiyama K, Ishii KJ, Wakita T, Akari H, Kato T. Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model. Gut 2018;67:372-9. [PMID: 27797937 DOI: 10.1136/gutjnl-2016-312208] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
24 Lee EM, Alsagheir A, Wu X, Hammack C, McLauchlan J, Watanabe N, Wakita T, Kneteman NM, Douglas DN, Tang H. Hepatitis C Virus-Induced Degradation of Cell Death-Inducing DFFA-Like Effector B Leads to Hepatic Lipid Dysregulation. J Virol 2016;90:4174-85. [PMID: 26865724 DOI: 10.1128/JVI.02891-15] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Jhaveri R, Swamy GK. Hepatitis C Virus in Pregnancy and Early Childhood: Current Understanding and Knowledge Deficits. J Pediatric Infect Dis Soc 2014;3 Suppl 1:S13-8. [PMID: 25232471 DOI: 10.1093/jpids/piu045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
26 Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol. 2013;11:688-700. [PMID: 24018384 DOI: 10.1038/nrmicro3098] [Cited by in Crossref: 248] [Cited by in F6Publishing: 229] [Article Influence: 27.6] [Reference Citation Analysis]
27 García-Sacristán A, Moreno M, Ariza-Mateos A, López-Camacho E, Jáudenes RM, Vázquez L, Gómez J, Martín-Gago JÁ, Briones C. A magnesium-induced RNA conformational switch at the internal ribosome entry site of hepatitis C virus genome visualized by atomic force microscopy. Nucleic Acids Res 2015;43:565-80. [PMID: 25510496 DOI: 10.1093/nar/gku1299] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
28 Gane E, Stedman C, Dole K, Chen J, Meyers CD, Wiedmann B, Zhang J, Raman P, Colvin RA. A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial. ACS Infect Dis 2017;3:144-51. [PMID: 27788579 DOI: 10.1021/acsinfecdis.6b00138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Kleiner DE, Berk PD, Hsu JY, Courcoulas AP, Flum D, Khandelwal S, Pender J, Pomp A, Roerig J, Machado LL, Wolfe BM, Belle SH; LABS Consortium. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis 2014;34:98-107. [PMID: 24782263 DOI: 10.1055/s-0034-1371083] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
30 Dai CY, Tsai YS, Chou WW, Liu T, Huang CF, Wang SC, Tsai PC, Yeh ML, Hsieh MY, Huang CI, Vanson Liu SY, Huang JF, Chuang WL, Yu ML. The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection. Oncotarget 2018;9:11291-302. [PMID: 29541414 DOI: 10.18632/oncotarget.24129] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
31 Rockstroh JK, Bhagani S. Managing HIV/hepatitis C co-infection in the era of direct acting antivirals. BMC Med. 2013;11:234. [PMID: 24228933 DOI: 10.1186/1741-7015-11-234] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
32 Pawlotsky JM. What are the pros and cons of the use of host-targeted agents against hepatitis C? Antiviral Res. 2014;105:22-25. [PMID: 24583032 DOI: 10.1016/j.antiviral.2014.02.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
33 Han T, Wan Y, Wang J, Zhao P, Yuan Y, Wang L, She Y, Broering R, Lu M, Ye L, Zhu Y. Set7 facilitates hepatitis C virus replication via enzymatic activity-dependent attenuation of the IFN-related pathway. J Immunol. 2015;194:2757-2768. [PMID: 25681344 DOI: 10.4049/jimmunol.1400583] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
34 Murayama A, Sugiyama N, Wakita T, Kato T. Completion of the Entire Hepatitis C Virus Life Cycle in Vero Cells Derived from Monkey Kidney. mBio 2016;7:e00273-16. [PMID: 27302754 DOI: 10.1128/mBio.00273-16] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
35 Ajlan A, Al-Jedai A, Elsiesy H, Alkortas D, Al-Hamoudi W, Alarieh R, Al-Sebayel M, Broering D, Aba Alkhail F. Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients. Can J Gastroenterol Hepatol 2016;2016:2872371. [PMID: 27446833 DOI: 10.1155/2016/2872371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
36 Crosignani A, Riva A, Della Bella S. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol 2016; 22(4): 1393-1404 [PMID: 26819508 DOI: 10.3748/wjg.v22.i4.1393] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
37 Pfaender S, Walter S, Todt D, Behrendt P, Doerrbecker J, Wölk B, Engelmann M, Gravemann U, Seltsam A, Steinmann J, Burbelo PD, Klawonn F, Feige K, Pietschmann T, Cavalleri JV, Steinmann E. Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. J Gen Virol 2015;96:2636-42. [PMID: 26041875 DOI: 10.1099/vir.0.000208] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
38 Conway JM, Perelson AS. A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis. PLoS Comput Biol 2014;10:e1003769. [PMID: 25101902 DOI: 10.1371/journal.pcbi.1003769] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
39 Salvatierra K, Florez H. Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistance. F1000Res 2016;5:1141. [PMID: 27547378 DOI: 10.12688/f1000research.8740.2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Hundt J, Li Z, Liu Q. The inhibitory effects of anacardic acid on hepatitis C virus life cycle. PLoS One 2015;10:e0117514. [PMID: 25658101 DOI: 10.1371/journal.pone.0117514] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
41 Andre-Garnier E, Besse B, Rodallec A, Ribeyrol O, Ferre V, Luco C, Le Guen L, Bourgeois N, Gournay J, Billaud E, Raffi F, Coste-Burel M, Imbert-Marcille BM. An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains. PLoS One 2017;12:e0179562. [PMID: 28727784 DOI: 10.1371/journal.pone.0179562] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]